A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma

BACKGROUND: The objectives of this phase II study were to determine the clinical activity of the MET tyrosine kinase inhibitor capmatinib (INC280) in patients with MET-dysregulated advanced hepatocellular carcinoma (HCC) and to assess the safety, pharmacokinetics, and correlation of biomarkers with...

Descripción completa

Detalles Bibliográficos
Autores principales: Qin, Shukui, Chan, Stephen Lam, Sukeepaisarnjaroen, Wattana, Han, Guohong, Choo, Su Pin, Sriuranpong, Virote, Pan, Hongming, Yau, Thomas, Guo, Yabing, Chen, Minshan, Ren, Zhenggang, Xu, Jianming, Yen, Chia-Jui, Lin, Zhong-Zhe, Manenti, Luigi, Gu, Yi, Sun, Yongjian, Tiedt, Ralph, Hao, Lu, Song, Wenjie, Tanwandee, Tawesak
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6906348/
https://www.ncbi.nlm.nih.gov/pubmed/31853265
http://dx.doi.org/10.1177/1758835919889001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6906348/
https://www.ncbi.nlm.nih.gov/pubmed/31853265
http://dx.doi.org/10.1177/1758835919889001

Ejemplares similares